BioSpace News Archive

Eli Lilly and Company will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $6.9 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stoc

- Crinecerfont Demonstrates Meaningful Reductions in Key Disease Biomarkers After 14 Days of Treatment - Initiation of Global Registrational Study of Crinecerfont in Adults Planned for Second Half 2020 [08-June-2020] SAN DIEGO , June 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed op

Tests Facilitate Safe Clinical Care and Employer Health Programs, Also Available to General Public Through Web Order At-Home Saliva Test Gains Federal Approval After Rigorous Round of Validation Studies

Outcomes were equivalent for patients who had a total hip replacement with either an anterior incision approach or a posterior incision approach, according to an analysis of data from a matched group of patients who were treated at Hospital for Special Surgery (HSS) and discharged the same day.

Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune syste

Thermo Fisher Scientific today announced its Thermo Scientific NanoDrop PC Control software + Security Suite for NanoDrop One/One C can be used in compliance with U.S. Food and Drug Administratio

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Foo

Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). This is the first Phase 3 study of an investigational new drug for the treatment of Meniere’s Disease (MD), a neurotologic disease involving hearing loss, tinn